670 related articles for article (PubMed ID: 29559564)
21. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
22. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
Ko BW; Han J; Heo JY; Jang Y; Kim SJ; Kim J; Lee MJ; Ryu MJ; Song IC; Jo YS; Kweon GR
Leuk Lymphoma; 2016 Sep; 57(9):2180-8. PubMed ID: 26854822
[TBL] [Abstract][Full Text] [Related]
23. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
[TBL] [Abstract][Full Text] [Related]
24. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
25. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
26. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
27. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
28. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
29. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
30. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
[TBL] [Abstract][Full Text] [Related]
31. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
32. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
33. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
34. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
35. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
[TBL] [Abstract][Full Text] [Related]
36. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
Jiang X; Cheng Y; Hu C; Zhang A; Ren Y; Xu X
Leuk Lymphoma; 2019 Jul; 60(7):1709-1720. PubMed ID: 30516071
[TBL] [Abstract][Full Text] [Related]
38. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C
Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435
[TBL] [Abstract][Full Text] [Related]
39. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
Han Y; Ma Z
Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
[TBL] [Abstract][Full Text] [Related]
40. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
